ORB-011 by Orionis Biosciences for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ORB-011 overview

ORB-011 is under development for the treatment of solid tumors including triple-negative breast cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer squamous cell carcinoma, metastatic melanoma, bladder cancer, gastric cancer, transitional cell cancer (urothelial cell cancer), esophageal cancer, kidney cancer (renal cell cancer), ovarian cancer, liver cancer, colorectal cancer. The therapeutic candidate is a modified interferon and is administered through intravenous route. It is being developed based on A-Kine platform.

Orionis Biosciences overview

Orionis Biosciences is a biotechnology company that discover and develops drugs for the treatment of oncology, immunotherapies and diseases with high unmet medical needs. The company is headquartered in Waltham, Massachusetts, the US.

For a complete picture of ORB-011’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.